Review



mouse monoclonal anti ppar γ antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech mouse monoclonal anti ppar γ antibody
    Mouse Monoclonal Anti Ppar γ Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti ppar γ antibody/product/Proteintech
    Average 93 stars, based on 40 article reviews
    mouse monoclonal anti ppar γ antibody - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    mouse monoclonal anti ppar γ antibody  (Proteintech)
    93
    Proteintech mouse monoclonal anti ppar γ antibody
    Mouse Monoclonal Anti Ppar γ Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti ppar γ antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mouse monoclonal anti ppar γ antibody - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse anti pparγ  (Proteintech)
    93
    Proteintech mouse anti pparγ
    Mouse Anti Pparγ, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti pparγ/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mouse anti pparγ - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc mouse
    Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    mouse - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    mouse anti pparγ  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology mouse anti pparγ
    a, Changes in various lipid components in macrophages after IL-17A intervention. b-c, Enrichment analysis showing the main downregulated lipid types. d, Gene interaction network showing that PPARG is involved in three enrichment pathways: lipid homeostasis□cytokine-mediated signaling pathway□myeloid leukocyte differentiation. e, mRNA expression levels of PPARG, TREM2 in macrophages after IL-17A intervention. f, Immunofluorescence showing the spatial relationship between IL-17RA and <t>PPARγ.</t> g, mRNA expression levels of CXCL2, CXCL8, and TREM2 in macrophages after PPARγ agonist intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.
    Mouse Anti Pparγ, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti pparγ/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    mouse anti pparγ - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    1 ap mouse anti gapdh proteintech  (Proteintech)
    96
    Proteintech 1 ap mouse anti gapdh proteintech
    a, Changes in various lipid components in macrophages after IL-17A intervention. b-c, Enrichment analysis showing the main downregulated lipid types. d, Gene interaction network showing that PPARG is involved in three enrichment pathways: lipid homeostasis□cytokine-mediated signaling pathway□myeloid leukocyte differentiation. e, mRNA expression levels of PPARG, TREM2 in macrophages after IL-17A intervention. f, Immunofluorescence showing the spatial relationship between IL-17RA and <t>PPARγ.</t> g, mRNA expression levels of CXCL2, CXCL8, and TREM2 in macrophages after PPARγ agonist intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.
    1 Ap Mouse Anti Gapdh Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1 ap mouse anti gapdh proteintech/product/Proteintech
    Average 96 stars, based on 1 article reviews
    1 ap mouse anti gapdh proteintech - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    mouse anti-pparγ  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology mouse anti-pparγ
    a, Changes in various lipid components in macrophages after IL-17A intervention. b-c, Enrichment analysis showing the main downregulated lipid types. d, Gene interaction network showing that PPARG is involved in three enrichment pathways: lipid homeostasis□cytokine-mediated signaling pathway□myeloid leukocyte differentiation. e, mRNA expression levels of PPARG, TREM2 in macrophages after IL-17A intervention. f, Immunofluorescence showing the spatial relationship between IL-17RA and <t>PPARγ.</t> g, mRNA expression levels of CXCL2, CXCL8, and TREM2 in macrophages after PPARγ agonist intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.
    Mouse Anti Pparγ, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-pparγ/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse anti-pparγ - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a, Changes in various lipid components in macrophages after IL-17A intervention. b-c, Enrichment analysis showing the main downregulated lipid types. d, Gene interaction network showing that PPARG is involved in three enrichment pathways: lipid homeostasis□cytokine-mediated signaling pathway□myeloid leukocyte differentiation. e, mRNA expression levels of PPARG, TREM2 in macrophages after IL-17A intervention. f, Immunofluorescence showing the spatial relationship between IL-17RA and PPARγ. g, mRNA expression levels of CXCL2, CXCL8, and TREM2 in macrophages after PPARγ agonist intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.

    Journal: bioRxiv

    Article Title: IL-17A-driven Macrophage Disorder Promotes Plaque Instability in Psoriatic Atherosclerosis

    doi: 10.1101/2025.05.21.654491

    Figure Lengend Snippet: a, Changes in various lipid components in macrophages after IL-17A intervention. b-c, Enrichment analysis showing the main downregulated lipid types. d, Gene interaction network showing that PPARG is involved in three enrichment pathways: lipid homeostasis□cytokine-mediated signaling pathway□myeloid leukocyte differentiation. e, mRNA expression levels of PPARG, TREM2 in macrophages after IL-17A intervention. f, Immunofluorescence showing the spatial relationship between IL-17RA and PPARγ. g, mRNA expression levels of CXCL2, CXCL8, and TREM2 in macrophages after PPARγ agonist intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.

    Article Snippet: Primary antibodies included mouse anti-CD68 (GB12192, Servicebio), mouse anti-PPARγ (sc-136250, Santa Cruz Biotechnology), and rabbit anti-MIP2 (GB11130, Servicebio).

    Techniques: Expressing, Immunofluorescence

    a, mRNA expression levels of CD80, CD86 in macrophages after PPARγ agonist and IL-17A intervention. b, CD86 protein expression levels in macrophages after PPARγ agonist and IL-17A intervention. c, mRNA expression levels of CXCL2, CXCL3, CXCL8, CCL2, and CCL3 in macrophages after PPARγ agonist and IL-17A intervention. d, mRNA expression levels of TREM2,PLTP,APOE,FABP3 and FABP5 in macrophages after PPARγ agonist and IL-17A intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.

    Journal: bioRxiv

    Article Title: IL-17A-driven Macrophage Disorder Promotes Plaque Instability in Psoriatic Atherosclerosis

    doi: 10.1101/2025.05.21.654491

    Figure Lengend Snippet: a, mRNA expression levels of CD80, CD86 in macrophages after PPARγ agonist and IL-17A intervention. b, CD86 protein expression levels in macrophages after PPARγ agonist and IL-17A intervention. c, mRNA expression levels of CXCL2, CXCL3, CXCL8, CCL2, and CCL3 in macrophages after PPARγ agonist and IL-17A intervention. d, mRNA expression levels of TREM2,PLTP,APOE,FABP3 and FABP5 in macrophages after PPARγ agonist and IL-17A intervention. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the One-way ANOVA.

    Article Snippet: Primary antibodies included mouse anti-CD68 (GB12192, Servicebio), mouse anti-PPARγ (sc-136250, Santa Cruz Biotechnology), and rabbit anti-MIP2 (GB11130, Servicebio).

    Techniques: Expressing

    a, RNA sequencing data showing mRNA changes in mouse bone marrow primary macrophages after IL-17A inhibition. b, GO enrichment analysis of differential genes in bone marrow primary macrophages between IL-17A inhibitor-treated and control groups. c, KEGG enrichment analysis of differential genes in bone marrow primary macrophages between IL-17A inhibitor-treated and control groups. d, Immunofluorescence showing changes in MIP2 and PPARγ in the abdominal aorta between IL-17A inhibitor-treated and control groups. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the t-test.

    Journal: bioRxiv

    Article Title: IL-17A-driven Macrophage Disorder Promotes Plaque Instability in Psoriatic Atherosclerosis

    doi: 10.1101/2025.05.21.654491

    Figure Lengend Snippet: a, RNA sequencing data showing mRNA changes in mouse bone marrow primary macrophages after IL-17A inhibition. b, GO enrichment analysis of differential genes in bone marrow primary macrophages between IL-17A inhibitor-treated and control groups. c, KEGG enrichment analysis of differential genes in bone marrow primary macrophages between IL-17A inhibitor-treated and control groups. d, Immunofluorescence showing changes in MIP2 and PPARγ in the abdominal aorta between IL-17A inhibitor-treated and control groups. Significance indicated as *P < 0.05, **P < 0.01, ***P < 0.001, with ns denoting not significant. Statistical analysis was performed using the t-test.

    Article Snippet: Primary antibodies included mouse anti-CD68 (GB12192, Servicebio), mouse anti-PPARγ (sc-136250, Santa Cruz Biotechnology), and rabbit anti-MIP2 (GB11130, Servicebio).

    Techniques: RNA Sequencing, Inhibition, Control, Immunofluorescence

    Psoriasis mediates atherosclerotic plaque destabilization through IL-17A–IL-17RA–mediated downregulation of PPARγ in macrophages, leading to macrophage disorganization characterized by increased inflammation, production of inflammatory factors, and downregulation of sphingomyelin components.

    Journal: bioRxiv

    Article Title: IL-17A-driven Macrophage Disorder Promotes Plaque Instability in Psoriatic Atherosclerosis

    doi: 10.1101/2025.05.21.654491

    Figure Lengend Snippet: Psoriasis mediates atherosclerotic plaque destabilization through IL-17A–IL-17RA–mediated downregulation of PPARγ in macrophages, leading to macrophage disorganization characterized by increased inflammation, production of inflammatory factors, and downregulation of sphingomyelin components.

    Article Snippet: Primary antibodies included mouse anti-CD68 (GB12192, Servicebio), mouse anti-PPARγ (sc-136250, Santa Cruz Biotechnology), and rabbit anti-MIP2 (GB11130, Servicebio).

    Techniques: